Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Molecular Characterization of the Resistance of Mycobacterium tuberculosis to Second Line Drugs in Côte d’Ivoire

T Ouassa1 , YG Loukou1, A Dotia1, H Faye-Kette2

1Department of Bacteriology and Virology, Faculty of Pharmaceutical and Biological Sciences. University Félix Houphouët-Boigny, BP V34 Abidjan, Côte d’Ivoire; 2Department of Bacteriology and Virology, Faculty of Medical Sciences. University Félix Houphouët-Boigny, BP V34 Abidjan, Côte d’Ivoire.

For correspondence:-   Ouassa   Email: timouassa@yahoo.fr   Tel:+22502500078

Received: 14 June 2013        Accepted: 12 March 2014        Published: 23 May 2014

Citation: Ouassa T, Loukou Y, Dotia A, Faye-Kette H. Molecular Characterization of the Resistance of Mycobacterium tuberculosis to Second Line Drugs in Côte d’Ivoire. Trop J Pharm Res 2014; 13(5):727-730 doi: 10.4314/tjpr.v13i5.11

© 2014 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To characterize the resistance of Mycobacterium tuberculosis to second line drugs using a line probe assay.
Methods: Multi-drug resistant strains of Mycobacterium tuberculosis isolated between December 2008 and December 2009 were tested for resistance to fluoroquinolones and second-line injectable drugs using GenoType® MTBDRsl.
Results: Thirty eight strains gave interpretable results. None of them had a mutation in the gyrA gene. Regarding second-line injectable drugs, 4 strains (11 %) were resistant to aminoglycosides/ capreomycin and all of them harbored A1401G mutation.
Conclusion: No extensive drug resistant strains were observed. A relatively high proportion of strains were resistant to at least one second-line injectable drug. Resistance mechanism seemed similar for all of them.

Keywords: Mycobacterium tuberculosis, Line probe assay, GenoType® MTBDRsl, Aminoglycosides Capreomycin, Mutation

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10. 
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2013; 12: 
1,   2,   3,   4,   5,   6. 
2012; 11: 
1,   2,   3,   4,   5,   6. 
2011; 10: 
1,   2,   3,   4,   5,   6. 
2010; 9: 
1,   2,   3,   4,   5,   6. 
2009; 8: 
1,   2,   3,   4,   5,   6. 
2008; 7: 
1,   2,   3,   4. 
2007; 6: 
1,   2,   3,   4. 
2006; 5: 
1,   2. 
2005; 4: 
1,   2. 
2004; 3: 
1. 
2003; 2: 
1,   2. 
2002; 1: 
1,   2. 

News Updates